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An older dog with newer tricks
Predicting efficacy of IFN-b treatment for multiple sclerosis
A building optimism for individually tailored ther-
apy has been integrated into the burgeoning land-
scape of treatment options for multiple sclerosis
(MS).1 In spite of ongoing advances in imaging
and the understanding of MS pathogenesis, predict-
ing which therapies will be most effective for indi-
viduals with MS has remained elusive. In this issue,
Hegen et al.2 report on the use of serum cytokine
analysis to explore predictors of MS patient re-
sponses to interferon-b (IFN-b) therapy. They per-
form Luminex cytokine quantification from serum
of patients with either clinically isolated syndrome
or relapsing MS before and 3 months after treatment
with IFN-b. Using hierarchical clustering analysis,
they stratify patients into 6 groups according to
baseline cytokine expression and find that these
groupings provide meaningful discrimination
between patients’ subsequent clinical responses to
IFN-b treatment.
As an extension of the authors’ prior studies in
experimental murine systems and in human patients
with MS,3 the results undoubtedly promote the
notion that there could be clinical utility in quanti-
fying circulating cytokines before the initiation of
disease-modifying therapy. Before this is incorporated
into clinical practice, it will be important to deter-
mine whether the classification of patients into
groups according to baseline cytokine phenotypes is
stable over time. The authors base their classification
on a single blood draw before initiating IFN-b ther-
apy. However, intra-individual variability in circu-
lating cytokines can occur,4,5 as circulating immune
markers vary for many reasons, including the overall
health of the individual and exposure to other med-
ications.6 Assay technique can also be a limiting var-
iable.7 In this article, the authors make no mention
of patients’ prior exposure to other disease-
modifying therapies for MS, but other work using
this patient cohort suggests that not all patients were
treatment-naive.8 As illustrated by the reported re-
sults, exposure to disease-modifying therapy changes
the profile of circulating cytokines. Hence, longitu-
dinal data demonstrating that patients consistently
fall into the same cytokine group should be taken
into consideration before clinical utility can be seri-
ously considered.
The current study used several definitions for
IFN-b nonresponders, which are worth noting.
One definition was based on annualized relapse rate
(ARR) for the 2 years before IFN-b treatment com-
pared to the 2 years after treatment. Relapses were
defined based only on history; no objective demon-
stration of a neurologic deficit was required. It should
also be noted that the ARR was higher for IFN-b
nonresponders than for responders during the 2 years
before the study. This raises the question as to
whether nonresponders simply had more active MS
in general. The reported data may thus distinguish
between patients with more active vs less active MS,
as opposed to indicating an effect of IFN-b treat-
ment. The authors alternatively defined nonrespond-
ers as patients who experienced a 1-point increase in
Expanded Disability Status Scale (EDSS) score
between baseline and 2 years post- IFN-b treatment.
Nonresponders had lower baseline EDSS scores than
responders, and both groups had mild disability, with
mean scores of 1.8 for responders and 1.2 for non-
responders. Because the EDSS is a nonlinear scale, a
clinically insignificant neurologic change can result in
a 1-point increase on the low end of the scale. This
may have biased the categorization of patients as res-
ponders or nonresponders. Careful selection of
patient groups, and an expansion of the number of
participants, will undoubtedly be useful in validating
the observations made regarding IFN-b responsive-
ness to date.
In summary, Hegen et al. report on an important
approach for subdividing patients with MS based on
their baseline level of circulating cytokines. This clas-
sification correlated with patients’ subsequent clinical
outcomes. Should these findings be reproduced with
a larger number of observations and increased rigor of
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defining outcomes, this strategy would have a sub-
stantial influence on the way treatment decisions are
made for patients with MS. Furthermore, the use
IFN-b, which has been decaying in the face of a rapid
expansion of therapeutic options,9 may be reinvigo-
rated by a more precise indication specific to this class
of disease-modifying therapy. On the other hand, the
approach of preassessing the likelihood of responsive-
ness to disease-modifying MS therapy is not exclusive
to IFN-b. Indeed, several studies on predictors of
efficacy for other disease-modifying treatments have
been reported. A report on the factors associated with
responsiveness to natalizumab serves as one example,
which notably examined MRI and CSF features in a
prospective trial.10 It is not unreasonable to speculate
that these additional variables in combination with
serum cytokine levels could provide even greater res-
olution for predicting response to disease-modifying
treatment in MS. Once it becomes possible to discern
the critical elements driving responsiveness to indi-
vidual disease-modifying therapies, understanding of
the pathogenesis of MS will certainly be enhanced
and tailored therapy for individual patients with MS
can truly be realized.
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